Tolvaptan (Jynarque)
Customize your policy alerts
Sign up for Cigna Policy IP0287 alerts
Get alerted when Policy IP0287 changes without checking for updates manually.
Monitor payer policy activity
Defines Cigna's prior authorization and medical necessity criteria for tolvaptan (Jynarque and generic) for treatment of autosomal dominant polycystic kidney disease (ADPKD) in adults; applies to Cigna-administered health benefit plans. Providers must follow the policy when requesting coverage.
The requirement regarding kidney function was updated to require a baseline estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2 rather than exclusion of Stage 5 CKD.
Examples of rapidly declining renal function were added, including eGFR decline ≥ 3.0 mL/min/1.73 m2 and Mayo Classification 1C, 1D, or 1E.
Policy name updated and Jynarque tablets are now available as a generic product; preferred product table for employer plans specifies trial of generic before brand under specified circumstances.
Added requirement that a patient on tolvaptan therapy cannot be on renal replacement therapy and defined renal replacement therapy as dialysis or transplantation.
Coverage Criteria for Tolvaptan (Jynarque and Generic)
FDA-Approved Indication (Initial Therapy)
Approve for 1 year if the patient meets ALL of the following (A–F):
Initial approval duration = 1 year
Autosomal Dominant Polycystic Kidney Disease
Covered when ALL of the following are met
ADPKD baseline and therapy exclusions
- Baseline kidney function: Baseline estimated glomerular filtration rate (eGFR) is >= 25 mL/min/1.73 m2 prior to any tolvaptan treatment.eGFR >= 25 mL/min/1.73 m2
Baseline defined as prior to treatment with any tolvaptan product.
- Not on renal replacement therapy: Patient is not on renal replacement therapy (no dialysis or kidney transplantation).
Renal replacement therapy defined as dialysis or transplantation.
Use of tolvaptan products for indications other than the FDA‑approved treatment of autosomal dominant polycystic kidney disease (ADPKD) is considered not medically necessary under this policy. Examples include use for hyponatremia (where an alternative tolvaptan product, Samsca, is the indicated therapy) and concomitant use with Samsca, which is not recommended.
Patients who are receiving renal replacement therapy are excluded from tolvaptan therapy under this policy. Renal replacement therapy is defined as dialysis or kidney transplantation; requests for tolvaptan for patients on dialysis or after renal transplantation do not meet the coverage criteria.
Tolvaptan products prescribed for non‑ADPKD indications are considered not medically necessary. For example, clinically significant hyponatremia should be treated with the tolvaptan product indicated for that condition (Samsca) rather than using tolvaptan intended for ADPKD, and concomitant use of different tolvaptan products is not recommended.
Key Clinical Thresholds and Coding-related Metrics
Prior Authorization, Documentation, and Provider Requirements
Prior authorization required; approvals for 1 year and specialist involvement
Prior authorization is required for benefit coverage of tolvaptan. All approvals are provided for the duration noted (initial approval = 1 year) and require the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated (nephrologist).
- Initial approval duration = 1 year.
- Must be prescribed by or in consultation with a nephrologist.
Prior authorization requires baseline eGFR and absence of renal replacement therapy
Prior authorization is required for tolvaptan products (Jynarque and generic) with criteria that include a documented baseline estimated glomerular filtration rate (eGFR) and that the patient is not on renal replacement therapy (dialysis or kidney transplantation).
- Baseline eGFR requirement: ≥ 25 mL/min/1.73 m2 (baseline defined as prior to treatment with any tolvaptan product).
- Patient must not be on renal replacement therapy (defined as dialysis or kidney transplantation).
Employer plans: trial of bioequivalent generic required before brand
For Employer Plans, the patient must have tried the bioequivalent generic tolvaptan tablets before brand Jynarque unless the patient cannot take the generic due to a formulation difference in inactive ingredient(s) that would cause, per the prescriber, a significant allergy or serious adverse reaction.
- Trial of bioequivalent generic required before brand for Employer Plans.
- Exemption allowed if inactive ingredient difference causes significant allergy or serious adverse reaction (per prescriber).
Preferred product reference — Employer Plans Preferred Product table (generic availability)
See Employer Plans Preferred Product table referenced in the revision details; Jynarque tablets are now available as a generic product and the preferred product table applies (no criteria changes to Jynarque tablets or therapy pack).
- Jynarque tablets are now available as a generic product.
- Employer Plans Preferred Product table referenced for preferred product rules; no criteria changes for tablets or therapy pack.
Required clinical documentation: age, rapidly progressing ADPKD, baseline eGFR, and specialist involvement
Prescriber documentation must show the patient is ≥ 18 years of age, that the patient has rapidly progressing ADPKD (as stated by the prescriber), the baseline eGFR value (≥ 25 mL/min/1.73 m2), and that the patient is not on renal replacement therapy; the medication must be prescribed by or in consultation with a nephrologist.
- Age ≥ 18 documented.
- Prescriber statement of rapidly progressing ADPKD (examples include eGFR decline ≥ 3.0 mL/min/1.73 m2 or Mayo Classification 1C–1E).
- Baseline eGFR value documented (≥ 25 mL/min/1.73 m2).
- Documentation that patient is not on renal replacement therapy (dialysis or transplant).
- Medication prescribed by or in consultation with a nephrologist.
Baseline eGFR documentation required (eGFR ≥ 25 mL/min/1.73 m2 prior to any tolvaptan)
Baseline eGFR documentation is required to show an eGFR ≥ 25 mL/min/1.73 m2 prior to treatment with any tolvaptan product; baseline is defined as prior to any tolvaptan therapy and documentation that the patient is not on renal replacement therapy is also required.
- Baseline defined as prior to treatment with any tolvaptan product.
- Required baseline threshold: eGFR ≥ 25 mL/min/1.73 m2.
- Document absence of renal replacement therapy (dialysis or transplantation).
Denial risk if no prior authorization or for non-ADPKD indications (including hyponatremia)
Requests submitted without prior authorization or requests for uses other than ADPKD (including hyponatremia) will be denied as not medically necessary.
- Tolvaptan for non-ADPKD indications (e.g., hyponatremia) is considered not medically necessary under this policy.
- Concomitant use with Samsca (other tolvaptan product for hyponatremia) is not recommended.
Denial triggers: baseline eGFR < 25 or patient on renal replacement therapy
Requests may be denied if the patient’s baseline eGFR is < 25 mL/min/1.73 m2 or if the patient is on renal replacement therapy (dialysis or kidney transplantation).
- Denial trigger: baseline eGFR less than 25 mL/min/1.73 m2.
- Denial trigger: patient on renal replacement therapy (dialysis or transplantation).
Clinical Background
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder characterized by progressive renal cyst growth, enlargement of the kidneys, and progressive decline in kidney function that can lead to end‑stage renal disease. Tolvaptan is indicated to slow kidney function decline in adults with ADPKD who are at risk of rapidly progressing disease.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.